Faeth Therapeutics Inc. Common Stock (FTH)
Stock · NASDAQ · Health Care
$18.76as of 10/16/2026
Price chart
Active signals
FTH Signal Track Record
How signals performed across all stocks →What FTH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 26 | -12.0% | 35% | September 2, 2026 |
| Volume Spike | 21 | -10.9% | 24% | September 18, 2026 |
| Bollinger Band Breakdown | 19 | +0.4% | 53% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +4.4% | 58% | June 2, 2026 |
| Any 20-session window (baseline) | -2.5% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FTH
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- www.senseibio.com
Fundamentals
- 1-day range
- $19.9$21.39
- Market cap
- $632.57M
- P/E (trailing)
- —
- P/E (forward)
- -4.59
- EPS (trailing)
- $-141.65
- Dividend yield
- —
- Beta
- 2.31
- Avg. volume
- 350.1K
Forecasts
12 analyst ratings
Faeth Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FTHFaeth Therapeutics Inc. Common Stock$18.8▼ 8.74%Market cap $632.57MP/E —$13.43$42.14
- NVCTNuvectis Pharma Inc. Common Stock$18.6▼ 1.74%Market cap $613.51MP/E —$5.55$29.28
- CBIOCrescent Biopharma Inc. Common Stock$11.84▼ 5.13%Market cap $610.27MP/E —$8.72$27.41
- FBIOPFortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock$16.67▼ 1.30%Market cap $662.39MP/E 0.58$1.88$4.53
- MPLTMapLight Therapeutics Inc. Common Stock$7.7▼ 3.99%Market cap $602.19MP/E —$8.7$40.43
- CRMDCorMedix Inc. Common Stock$7.26▼ 2.68%Market cap $589.17MP/E 3.11$6.13$13.02
- PHATPhathom Pharmaceuticals Inc. Common Stock$6.92▼ 7.73%Market cap $678.76MP/E —$6.52$18.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FTH Faeth Therapeutics Inc. Common Stock | $632.57M | — | $18.8 | ▼ 8.74% | $13.43$42.14 |
| NVCT Nuvectis Pharma Inc. Common Stock | $613.51M | — | $18.6 | ▼ 1.74% | $5.55$29.28 |
| CBIO Crescent Biopharma Inc. Common Stock | $610.27M | — | $11.84 | ▼ 5.13% | $8.72$27.41 |
| FBIOP Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock | $662.39M | 0.58 | $16.67 | ▼ 1.30% | $1.88$4.53 |
| MPLT MapLight Therapeutics Inc. Common Stock | $602.19M | — | $7.7 | ▼ 3.99% | $8.7$40.43 |
| CRMD CorMedix Inc. Common Stock | $589.17M | 3.11 | $7.26 | ▼ 2.68% | $6.13$13.02 |
| PHAT Phathom Pharmaceuticals Inc. Common Stock | $678.76M | — | $6.92 | ▼ 7.73% | $6.52$18.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Faeth Therapeutics with Outperform Ratingbenzinga · 10/16/2026
- Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial ReadoutYahoo · 10/7/2026
- Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug ExpansionSeekingAlpha · 9/18/2026
- Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of DirectorsYahoo · 9/17/2026
- Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70Benzinga · 9/16/2026
- LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59Benzinga · 9/14/2026
Insider Activity
Insider Actions →- Vousden Karen H · September 11, 2026 · Grant25.0K
- Anand Kiran Parikh · July 21, 2026 · Grant398.0K
- Craver Josiah · July 21, 2026 · Grant30.8K
- Brian C. Stephenson · July 1, 2026 · Buy600 @ $24.22
- Brian C. Stephenson · July 1, 2026 · Buy4.4K @ $23.4
- Brian C. Stephenson · June 30, 2026 · Buy4.3K @ $24.98
- Brian C. Stephenson · June 30, 2026 · Buy1.6K @ $23.88
- Brian C. Stephenson · June 30, 2026 · Buy1.9K @ $22.95
- Brian C. Stephenson · June 29, 2026 · Buy831 @ $23.34
Institutional Ownership
March 31, 2026
- Total shares held
- 2.51M
- Total value held
- $77.32M
- Institutional holders
- 29
- Unknown722.0K
- Unknown361.0K
- Unknown306.2K
- Unknown146.6K
- Unknown133.5K
- Unknown132.9K
- Unknown126.0K
- Unknown125.0K
- Unknown65.7K
- Unknown61.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
William Blair Begins Coverage of Faeth Therapeutics (FTH)
William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.
William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.